Despite intensive research, however, the immediate consequences of MyD88L265P expression in lymphoma cells, the exact molecular mechanism of MyD88 oncogenic signaling, and its role in other pathways beyond NF-kB activation remain unresolved. Here, NFKB1 is linked to lymphoma.